Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195826 | 1.00 | LIG1 (0.68) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL22799630 | 0.87 | KDM4E (0.59) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL10542058 | 0.87 | LIG1 (0.67) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL11239113 | 0.86 | LIG1 (0.55) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL3937140 | 0.86 | LIG1 (0.55) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL2431626 | 0.86 | LIG1 (0.55) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL8399357 | 0.85 | ALDH1A1 (0.54) | LIG1KDM4ESLC6A3HSP90AA1MAPT | |
| SCHEMBL174686 | 0.85 | CYP3A4 (0.74) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL28576934 | 0.84 | KDM4E (0.68) | LIG1ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL7314986 | 0.84 | ADRB2 (0.60) | LIG1ADRB2ADRB1ADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002442-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2025-01-02 | — | — | US | disclosed |
| CN-115228618-A | Application of O-allyl salicylhydroxamic acid compound in metal ore flotation | 中南大学 | 2022-10-25 | — | — | CN | disclosed |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| CN-108191957-B | Tripeptide macrocyclic derivatives, preparation method and application thereof | 浙江大学 | 2021-05-04 | — | — | CN | disclosed |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3209415-B1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORP (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190233362-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2019-08-01 | — | — | US | disclosed |
| US-10196342-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-5688751-A | ANTIDEPOSIT AGENT | THE LUBRIZOL CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| US-5654471-A | Process for the preparation of 4-hydroxyphenyl benzoate derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1997-08-05 | — | — | US | disclosed |
| EP-0686185-A4 | OVERBASED ALKYLATED ALKYL SALICYLATES | CHEVRON CHEM CO (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0686140-A4 | ALKYLATION OF ALKYL SALICYLATE USING A LONG CHAIN CARBON FEED | CHEVRON CHEM CO (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0686185-A1 | OVERBASED ALKYLATED ALKYL SALICYLATES | CHEVRON CHEMICAL COMPANY (US) | 1995-12-13 | — | — | EP | disclosed |
| EP-0686140-A1 | ALKYLATION OF ALKYL SALICYLATE USING A LONG CHAIN CARBON FEED | CHEVRON CHEMICAL COMPANY (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5434293-A | Sulfonic acid resin catalyst | CHEVRON CHEMICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995017486-A1 | OVERBASED ALKYLATED ALKYL SALICYLATES | CHEVRON CHEMICAL COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017370-A1 | ALKYLATION OF ALKYL SALICYLATE USING A LONG CHAIN CARBON FEED | CHEVRON CHEMICAL COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5415792-A | Overbased alkylated alkyl salicylates | CHEVRON CHEMICAL COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGS2 | LIG1 3170/4885ADRB2 248/4885ADRB1 895/4885 |
| US-20250002442-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
| US-20190233362-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
| US-10196342-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | LIG1 2625/4885ADRB2 1474/4885ADRB1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.